当前位置: 首页 >> 检索结果
101. In hypertension with high CV risk, intensive vs. standard BP-lowering therapy improved HRQoL by a small amount at a median 3.4 y.
GIM/FP/GP: [Formula: see text] Cardiology: [Formula: see text].
102. Optimizing Cervical Cancer Screening by Age at Vaccination for Human Papillomavirus: Health and Resource Implications.
作者: Kine Pedersen.;Jacopo Di Silvestre.;Stephen Sy.;Allison Portnoy.;Philip E Castle.;Jane J Kim.;Emily A Burger.
来源: Ann Intern Med. 2026年
Widespread vaccination for human papillomavirus (HPV) alters the landscape of cervical cancer (CC) risk, requiring adaptations to the CC screening program.
104. Alteplase and aspirin within 4.5 h of severe vision loss due to CRAO did not differ for improvement in visual acuity at 1 mo.
Emergency Med: [Formula: see text] Neurology: [Formula: see text].
109. In severe chronic rhinosinusitis with polyps and asthma, dupilumab improved nasal polyp score and sense of smell vs. omalizumab at 24 wk.
GIM/FP/GP: [Formula: see text] Allerg & Immunol: [Formula: see text] Pulmonology: [Formula: see text].
114. In knee OA, aerobic and mixed exercise reduce pain, and mind-body exercise improves function.
作者: Marius Henriksen.;Michelle Hall.;David J Hunter.;Shiwen Yuan.; .
来源: Ann Intern Med. 2026年179卷2期JC23页
GIM/FP/GP: [Formula: see text] Phys Med & Rehab: [Formula: see text].
115. In adults hospitalized with CAP, adding low-dose glucocorticoids to standard care reduced all-cause mortality at 30 d.
GIM/FP/GP: [Formula: see text] Infectious Disease: [Formula: see text] Pulmonology: [Formula: see text].
116. In patients with ischemic stroke, NVAF, and ASCVD, adding an antiplatelet to OAC therapy did not affect net clinical benefit at 2 y.
GIM/FP/GP: [Formula: see text] Neurology: [Formula: see text] Hematology: [Formula: see text].
117. Care of Bereaved Persons : A Systematic Review.
作者: Sangeeta Ahluwalia.;Julia Bandini.;Margaret Maglione.;Jeremy Miles.;Kelsey O'Hollaren.;Diana Zhang.;Manasi Yedavalli.;Sachi Yagyu.;Aneesa Motala.;Susanne Hempel.
来源: Ann Intern Med. 2026年
Bereavement after the death of someone close is universal, and clinicians may be uncertain if or what interventions may be beneficial.
118. Unexplained Pauses in Centers for Disease Control and Prevention Surveillance: Erosion of the Public Evidence Base for Health Policy.
作者: Jeremy W Jacobs.;Garrett S Booth.;Noel T Brewer.;Janet Freilich.
来源: Ann Intern Med. 2026年179卷3期425-429页
Real-time federal surveillance of diseases and health care delivery informs clinical guidance and public health policy. However, in 2025, some U.S. Centers for Disease Control and Prevention (CDC) databases seemed to have "unexplained pauses" and ceased or delayed updates. The CDC public data catalog was audited to identify paused databases that had previously been updated at least monthly and evaluated their characteristics. Of 1359 catalog records examined on 28 October 2025, eighty-two were previously updated at least monthly. On the basis of each database's stated periodicity, allowing for an additional 30-day grace period, their status was classified as either current or paused as of 28 October 2025. Forty-four databases (54%) were current, and 38 (46%) were paused. Thirty-four of the 38 databases (89%) had no data entries dated within 6 months of the date of analysis, whereas 4 (11%) paused more recently. Of the 38 paused databases, 33 (87%) were vaccination-related topics compared with none of the 44 current databases. Of the 5 paused databases on other topics, 4 addressed respiratory diseases, including disease burden and nonvaccine prevention measures, whereas 1 addressed public health (drug overdose deaths). The persistence of pauses as of 2 December 2025 was examined. Only 1 of the 38 paused databases had been updated. Such long pauses may have compromised evidence for decision making and policies by clinicians, administrators, professional organizations, and policymakers. Federal databases should adopt minimum transparency standards, including displaying the current update status, with a rationale if paused, and next expected update with criteria for resumption. Without such standards, unexplained pauses in surveillance risk undermining evidence-based medicine and public trust.
119. Impact of Study Hypotheses on Results From Randomized Clinical Trials: Comparison Between Standard and Noninferiority Randomized Clinical Trials.
作者: Yuanxi Jia.;Yiwen Jiang.;Peng Wu.;Qingping Yun.;Hao Wu.;Zhirong Yang.;Wei Wang.;Yang Song.;Wenyao Wang.;Yida Tang.;Yanhong Dong.;Karen A Robinson.;Jinling Tang.
来源: Ann Intern Med. 2026年179卷3期402-410页
In embarking on randomized clinical trials (RCTs), researchers can hypothesize that a more intensive treatment is better than a less intensive treatment (positive hypothesis) or that a less intensive treatment is similar or noninferior to a more intensive treatment (negative hypothesis). Researchers may design noninferiority RCTs (NI-RCTs) to support negative hypotheses and standard RCTs (S-RCTs) to support negative or positive hypotheses. Regardless of hypotheses, S-RCTs and NI-RCTs should produce consistent results when assessing similar participants, interventions, control, and outcomes.
120. Sodium Correction Rates and Associated Outcomes Among Patients With Severe Hyponatremia : A Retrospective Cohort Study.
作者: Dustin G Mark.;Mubarika Alavi.;Joshua R Nugent.;Mary E Reed.; .
来源: Ann Intern Med. 2026年179卷3期330-339页
Slow correction of severe hyponatremia is recommended to prevent osmotic demyelination syndrome but is associated with higher mortality.
|